top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Liver Attenuation.png
Frame 1000008251.jpg
Lung LAI.jpg
lung HAI.jpg
ٍEpicardial Fat .png
coronaryArteryCalcification.png
Thoracic Aorta and Pulmonary Artery Sizing .png
iScreen Shoter - 20261028184534618.jpg
Cardiac Chambers Volumetry.png
iScreen Shoter - 20261028184548151.jpg
aortic.jpg

Comparing AI-Enabled Opportunistic Detection of Lung Cancer on CAC Scans versus Chest CT: A Pooled MESA and Framingham Analysis

4 hours ago
2 min read

Submitted manuscript | Original research review

Lung cancer is often diagnosed in people who do not meet current screening criteria. This pooled cohort study examines whether an AI system can use coronary artery calcium (CAC) scans, obtained for cardiovascular assessment, to identify lung cancer opportunistically, and compares performance with paired chest CT.

Study design

The analysis included 3,816 participants from MESA Examination 5 and the Framingham Heart Study who had paired CAC and chest CT scans and at least two years of follow-up. The multi-model AI combined whole-chest analysis, nodule-focused assessment, and safety-net checks to classify scans as low, intermediate, or high likelihood. The outcome was lung cancer diagnosed within two years.

Key findings

Fifteen lung cancers were diagnosed during follow-up. The AI high-likelihood group captured 10 of 15 cancers on CAC scans (sensitivity 66.7%; positive predictive value [PPV] 7.5%) and 12 of 15 on chest CT (sensitivity 80.0%; PPV 5.9%). An automated nodule-size threshold of 8 mm yielded sensitivity/PPV of 73.3%/2.8% on CAC and 93.3%/2.3% on chest CT. For both scan types, PPV was higher for the AI high-likelihood group than for the size threshold. Two-year cancer rates in the AI low-likelihood groups were 0.14% on CAC and 0.0% on chest CT.

Interpretation

The results suggest that AI could identify lung cancer risk on CAC scans acquired for another clinical purpose, with higher PPV than the evaluated nodule-size threshold. This retrospective pooled-cohort analysis supports prospective evaluation; it does not establish that opportunistic AI screening improves patient outcomes.

Abstract

Background: Many lung cancers arise outside current screening eligibility criteria. Objective: To assess AI-enabled opportunistic lung cancer detection on CAC and paired chest CT scans versus a Fleischner-anchored nodule-size threshold. Methods: Pooled analysis of MESA and Framingham participants with paired scans; a multi-model AI assigned low-, intermediate-, or high-likelihood categories. The endpoint was lung cancer within two years. Results: Among 3,816 participants, 15 cancers were diagnosed. High-likelihood AI detected 10/15 on CAC (sensitivity 66.7%; PPV 7.5%) and 12/15 on chest CT (sensitivity 80.0%; PPV 5.9%). The automated 8-mm threshold had PPVs of 2.8% and 2.3%, respectively. Conclusions: AI showed higher PPV than the nodule-size threshold on both scan types, warranting prospective evaluation.

Status: Submitted to Radiology: Cardiothoracic Imaging. The full submitted manuscript is not attached.

Download the abstract

Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page